Clinical trials
Hyperlipoproteinemia Type II trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 4 |
| 2006 | 3 |
| 2007 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2016 | 4 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Recruiting | 4 |
| Terminated | 4 |
| Active, not recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Amgen | 3 |
| AstraZeneca | 2 |
| Genzyme, a Sanofi Company | 2 |
| Kastle Therapeutics, LLC | 2 |
| Medical Research Laboratories International | 2 |
| NewAmsterdam Pharma | 2 |
| Pfizer | 2 |
| REGENXBIO Inc. | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperlipoproteinemia Type II | 30 |
| Homozygous Familial Hypercholesterolemia | 11 |
| Hypercholesterolemia | 9 |
| Atherosclerosis | 5 |
| Cardiovascular Diseases | 5 |
| Dyslipidemias | 4 |
| Hyperlipidemias | 4 |
| Genetic Diseases, Inborn | 3 |
| Metabolic Diseases | 3 |
| Aortic Valve Stenosis | 2 |
Trials
Showing 26 to 30 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.